Literature DB >> 33585129

Low Absolute Eosinophil Count Predicts In-Hospital Mortality in Cirrhosis With Systemic Inflammatory Response Syndrome.

Varsha Wilson1, Kunnothara Kantan Velayudhan1, Harshavardhan Rao2, Sheejamol Velickakathu Sukumaran3.   

Abstract

Introduction Chronic liver disease (CLD) or Cirrhosis is one of the most common causes of morbidity as well as mortality. Child-Turcotte-Pugh (CTP) score and the model for end-stage liver disease (MELD) are useful to assess the long-term prognosis of a patient with CLD. When a patient with CLD is admitted with an acute illness leading to systemic inflammatory response syndrome (SIRS), these scores may not be reliable to predict the short-term prognosis and survival. Absolute eosinophils count (AEC) allows the rapid identification of patients at increased risk for sepsis-related mortality in patients. Methods This was a cross-sectional study conducted among patients in a tertiary care hospital in South India during a period of one and a half years between October 2018 and April 2020. Cirrhotic patients with SIRS aged between 16 years and 80 years were included in the study. AEC was measured as a part of automated complete blood counts. Patient demographics, lab parameters, and outcomes in terms of mortality were studied. Continuous variables were expressed as mean ± SD/median and categorical variables were expressed in frequency. Receiver operating characteristic (ROC) curve analysis was used to find an ideal cutoff for AEC in predicting hospital mortality. Multi-variate Cox regression analysis was performed to find predictors of mortality. Results A total of 100 patients who fit the pre-determined criteria for cirrhosis with SIRS were enrolled in the study. Sixteen (16%) patients died at the end of the study while 84 (84%) were alive. Using a ROC curve, the area under the curve (AUC) was 0.716 with 95% CI of AUC (0.564-0.867), the p-value was found to 0.006, a cut-off of eosinophil count of 198.5 cells/uL was found to be the cut-off for the prediction of in-hospital mortality in this subset of patients with cirrhosis and sepsis with SIRS, with a sensitivity of 75% and specificity of 38.1%. In a multi-variate Cox regression analysis, only age (hazard ratio {HR}: 1.175, 95%CI, 1.084 to 1.275, p<0.001) , CRP (HR : 1.008, 95%CI, 1.00 to 1.015, p=0.042) values, total leukocyte counts (TLC) (HR: 1.226, 95%CI, 1.116 to 1.346, p<0.001) and AEC (HR: 0.993, 95%CI, 0.987 to 0.999, p=0.016) were found to be statistically significant independent predictors of mortality. Conclusions The presence of eosinopenia may be considered as an in-expensive warning biomarker for poorer clinical outcomes in the form of in-hospital mortality in hospitalized cirrhotic patients. Other biomarkers such as CRP and TLC could also play a role both independently and in conjunction with AEC to predict outcomes and mortality in cirrhotic patients with sepsis and SIRS.
Copyright © 2021, Wilson et al.

Entities:  

Keywords:  absolute eosinophil count; chronic liver disease; cirrhosis; mortality; systemic inflammatory response syndrome

Year:  2021        PMID: 33585129      PMCID: PMC7872885          DOI: 10.7759/cureus.12643

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  12 in total

1.  Eosinopenia: Is it a good marker of sepsis in comparison to procalcitonin and C-reactive protein levels for patients admitted to a critical care unit in an urban hospital?

Authors:  Hamid Shaaban; Sunil Daniel; Raymond Sison; Jihad Slim; George Perez
Journal:  J Crit Care       Date:  2010-12       Impact factor: 3.425

2.  Eosinopenia as a diagnostic marker of bloodstream infection in hospitalised paediatric and adult patients: a case-control study.

Authors:  B A Wibrow; K M Ho; J P Flexman; A D Keil; D L Kohrs
Journal:  Anaesth Intensive Care       Date:  2011-03       Impact factor: 1.669

3.  Low eosinophil count predicts in-hospital mortality in cirrhosis with systemic inflammatory response syndrome.

Authors:  Hardik L Kotecha; Anil Arora; Romesh Chawlani; Jay Toshniwal; Naresh Bansal; Pankaj Tyagi; Praveen Sharma; Mandhir Kumar; Ashish Kumar
Journal:  Eur J Gastroenterol Hepatol       Date:  2013-06       Impact factor: 2.566

4.  Serum albumin as a risk factor for death in patients with prolonged sepsis: An observational study.

Authors:  Ryosuke Takegawa; Daijiro Kabata; Kentaro Shimizu; Saya Hisano; Hiroshi Ogura; Ayumi Shintani; Takeshi Shimazu
Journal:  J Crit Care       Date:  2019-02-04       Impact factor: 3.425

5.  Serum Albumin Trend Is a Predictor of Mortality in ICU Patients With Sepsis.

Authors:  Heather Kendall; Eduardo Abreu; An-Lin Cheng
Journal:  Biol Res Nurs       Date:  2019-02-05       Impact factor: 2.522

6.  A comparison of eosinopenia and C-reactive protein as a marker of bloodstream infections in critically ill patients: a case control study.

Authors:  K M Ho; S C Towler
Journal:  Anaesth Intensive Care       Date:  2009-05       Impact factor: 1.669

7.  Epidemiology and outcome of nosocomial bloodstream infection in elderly critically ill patients: a comparison between middle-aged, old, and very old patients.

Authors:  Stijn Blot; Mustafa Cankurtaran; Mirko Petrovic; Dominique Vandijck; Christelle Lizy; Johan Decruyenaere; Christian Danneels; Koenraad Vandewoude; Anne Piette; Gerda Vershraegen; Nele Van Den Noortgate; Renaat Peleman; Dirk Vogelaers
Journal:  Crit Care Med       Date:  2009-05       Impact factor: 7.598

8.  Eosinopenia is a reliable marker of sepsis on admission to medical intensive care units.

Authors:  Khalid Abidi; Ibtissam Khoudri; Jihane Belayachi; Naoufel Madani; Aicha Zekraoui; Amine Ali Zeggwagh; Redouane Abouqal
Journal:  Crit Care       Date:  2008-04-24       Impact factor: 9.097

9.  Relationship between Age and Peripheral White Blood Cell Count in Patients with Sepsis.

Authors:  Zohreh Aminzadeh; Elham Parsa
Journal:  Int J Prev Med       Date:  2011-10

10.  Better prognostic marker in ICU - APACHE II, SOFA or SAP II!

Authors:  Iftikhar Haider Naqvi; Khalid Mahmood; Syed Ziaullaha; Syed Mohammad Kashif; Asim Sharif
Journal:  Pak J Med Sci       Date:  2016 Sep-Oct       Impact factor: 1.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.